Achieving multi-isoform PI3K inhibition in a series of substituted 3,4-dihydro-2H-benzo[1,4]oxazines

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 16, 2008, Pages 4700-4704

  Perry, Benjamin ^a   Alexander, Rikki ^b   Bennett, Gavin ^a   Buckley, George ^a   Ceska, Tom ^b   Crabbe, Tom ^b   Dale, Verity ^a   Gowers, Lewis ^a   Horsley, Helen ^a   James, Lynwen ^a   Jenkins, Kerry ^a   Crépy, Karen ^b   Kulisa, Claire ^b   Lightfoot, Helen ^a   Lock, Chris ^a   Mack, Stephen ^a   Morgan, Trevor ^a   Nicolas, Anne Lise ^a   Pitt, Will ^a   Sabin, Verity ^a   Wright, Sara ^b   more..

^a World Wide Medicinal Chemistry   (United Kingdom)

^b UCB Celltech   (United Kingdom)

Author keywords

Inflammation; Isoform; Kinase; PI3K; Small molecule

Indexed keywords

OXAZINE DERIVATIVE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR;

ANIMAL EXPERIMENT; ARTICLE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; ENZYME INHIBITION; MALE; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; AREA UNDER CURVE; BENZOXAZINES; CHEMISTRY, PHARMACEUTICAL; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; HUMANS; INFLAMMATION; INHIBITORY CONCENTRATION 50; MODELS, CHEMICAL; MOLECULAR STRUCTURE; OXAZINES; PROTEIN ISOFORMS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 48849100158     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.06.104     Document Type: Article

References (19)

1. Cantley L.C. Science 296 (2002) 1655
2. Vanhaesebroeck B., Leevers S.J., Panayotou G., and Waterfield M.D. Trends Biochem. Sci. 22 (1997) 267
3. Crabbe T. Biochem. Soc. Trans. 35 (2007) 253
4. Rommel C., Camps M., and Ji H. Nat. Rev. Immunol. 7 (2007) 191
5. Vanhaesebroeck B., Ali K., Bilancio A., Geering B., and Foukas L.C. Trends Biochem. Sci. 30 (2005) 194
6. Clayton E., Bardi G., Bell S.E., Chantry D., Downes C.P., Gray A., Humphries L.A., Rawlings D., Reynolds H., Vigorito E., and Turner M. J. Exp. Med. 196 (2002) 753
7. Hirsch E., Katanaev V.L., Garlanda C., Azzolino O., Pirola L., Silengo L., Sozzani S., Mantovani A., Altruda F., and Wymann M. Science 287 (2000) 1049
8. CAS No. 15091-04-0.
9. Alexander, R.; Batchelor, M; Balasundaram, A.; Brookings, D.; Kitahara, K.; Kulisa, C; Turner, J.; Hutchinson, G.; Harris, S.; Wright, S. Bioorg. Med. Chem. Lett. 2008, 18, 4316
10. Alexander, R.; Aujla, P.; Batchelor, M.; Brookings, D.; Buckley, G.; Crepy, K.; Kulisa, C.; Turner, J. WO Patent 2006114606, 2006.
11. Anderson D.R., Meyers M.J., Vernier W.F., Mahoney M.W., Kurumbail R.G., Caspers N., Poda G.I., Schindler K.F., Reitz D.B., and Mourey R.J. J. Med. Chem. 50 (2007) 2647
12. Vanotti E., Amici R., Bargiotti A., Berthelsen J., Bosotti R., Ciavolella A., Cirla A., Cristiani C., D'Alessio R., Forte B., Isacchi A., Martina K., Menichincheri M., Molinari A., Montagnoli A., Orsini P., Pillan A., Roletto F., Scolaro A., Tibolla M., Valsasina B., Varasi M., Volpi D., and Santocanale C. J. Med. Chem. 51 (2008) 487
13. Butterworth, S.; Griffen, E.; Pass, M. WO Patent 2008032072, 2008.
14. Finlay, M.; Morris, J.; Pike, K. WO Patent 2008023159, 2008.
15. Hopkins A.L., Groom C.R., and Alex A. Drug Discov. Today 4 (2004) 430
16. PDB ID code 3DPD.
17. 50 > 15 μM). Compound 22n (10 μM) demonstrated >50% inhibition against 2 kinases from a panel of 50 (Pim-1 and SAPK2a).
18. Condliffe A.M., Davidson K., Anderson K.E., Ellson C.D., Crabbe T., Okkenhaug K., Vanhaesebroeck B., Turner M., Webb L., Wymann M.P., Hirsch E., Ruckle T., Campls M., Rommel C., Jackson S.P., Chilvers E.R., Stephens L.R., and Hawkins P.T. Blood 106 (2005) 1432
19. Alegre M.L., Tso J.Y., Sattar H.A., Smith J., Desalle F., Cole M., and Bluestone J.A. J. Immunol. 155 (1999) 1544